Callerio Foundation
NEWS - Siena, November 30 - December 1


The meeting “The Oncological Pharmacology: Between Innovation and Clinical Evidences ” organized by Professor Marina Ziche from University of Siena and sponsored by the Italian Society of Pharmacology, took place in Siena from November 30th to December 1st.

Researchers and Clinicians gave their points of views of on the progresses of therapies in Oncology, with a particular emphasis on the promising field of biomarkers and on the limits and toxicities of the so-called innovative compounds.

The Italian Agency of Drugs (AIFA) presented with the President (Professor Pecorelli) and Dott. Siviero, a novel instrument to evaluate the presence of “pharmacological innovation” in any new drug, an approach that takes into account the therapeutic aspects, the economical impact and the real medical and health need.
Dott. Pappagallo illustrated the crucial elements that a good clinical study needs to consider, and the mistakes sometimes hidden in a scientific work, and prof. Ziche highlited the importance of gender/sex differentiation in a clinical study, considering the different spreading of the pathologies and the different responses to the pharmacological treatments offered by women as compared to men.

The Congress provided also two sessions dedicated to young researchers. Among the many topics presented (e.g., the role of prostaglandins in tumour progression; an innovative technique to silence and detect at the same time mRNA through the use of functionalized oligonucleotides; the anti-migratory effects of cholesteroyl butyrate nanoparticles; new strategies to revert cancer multidrug resistance blocking transporter proteins as P-glycoproteins) some very interesting works focused on the pharmacological strategies towards the personalized therapies with clinical and genetic characterization to predict the chemotherapeutic activity and the clinical response in oncological patients also with the use of genetic markers and the combination of retrospective and prospective studies in order to limit the side effects and to improve patient’s survival.

Two young researchers were awarded for their excellence: dott. Eva Dreussi (CRO-National Cancer Institute of Aviano) who presented a microRNA-oriented strategy to select a SNPs panel of pharmacogenetic interest to tailor fluoropyrimidines to cancer patients, and dott. Gabriele Stocco (Department of Life Sciences, University of Trieste, and formerly Callerio Foundation Onlus) who presented the polymorphisms responsible for the thiopurine S-methyltransferase activity and the mercaptopurine-related gastrointestinal toxicity.

More information:

to the NEWS page